Skip to main content
SpringerLink
Log in
Book cover

Sjögren’s Syndrome pp 429–439Cite as

Measurement of Chronicity and Activity in Sjögren’s Syndrome

  • Chapter
  • First Online:

  • 1199 Accesses

Abstract

Systemic autoimmune conditions such as Sjögren’s syndrome (SS) are commonly characterized by prolonged episodes of activity, sustained by the underlying immunologic and inflammatory processes [1, 2]. The activity flares are clinically marked by the new appearance or worsening of signs and symptoms that are typical for each one of the different diseases. In some diseases, elevation of acute phase reactants or abnormalities of immunologic markers accompany active periods. If the active phase of the disease does not remit spontaneously or if remission is not achieved by treatment, a chronic phase of the disease may begin and irreversible damage can be produced in the involved organs and systems [1, 2].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Symmonds DPM. Disease assessment indices: activity, damage and severity. Baillieres Clin Rheumatol. 1995;9:267–85.

    Article  Google Scholar 

  2. Fries JF, Hochberg MC, Medsger TA. Criteria for rheumatic diseases: different types and different functions. Arthritis Rheum. 1994;37:454–62.

    Article  PubMed  CAS  Google Scholar 

  3. Liang MH. Translating outcomes measurement in experimental therapeutics of systemic rheumatic disease to patient care. Rheum Dis Clin North Am. 2006;32:1–8.

    Article  PubMed  Google Scholar 

  4. Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM. Sjögren’s syndrome: why autoimmune epithelitis? Oral Dis. 2006;12:523–32.

    Article  PubMed  CAS  Google Scholar 

  5. Garcia-Carrasco M, Ramos Casals M, Rasas J, et al. Primary Sjögren’s syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81:270–80.

    Article  Google Scholar 

  6. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long term risk of mortality and lymphoproliferative diseases and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum. 2002;46:741–7.

    Article  PubMed  Google Scholar 

  7. Ramos-Casals M, Brito-Zeron P. Emerging biological therapies in primary Sjögren’s syndrome. Rheumatology (Oxford). 2007;46:1389–96.

    Article  CAS  Google Scholar 

  8. Looney RJ. Will targeting B cells be the answer for Sjögren’s syndrome. Arthritis Rheum. 2007;56:1371–7.

    Article  PubMed  Google Scholar 

  9. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome. Ann Rheum Dis. 2007;66:351–7.

    Article  PubMed  CAS  Google Scholar 

  10. Szororay P, Jonnson R. The BAFF/APRIL system in systemic autoimmune diseases with special emphasis on Sjögren’s syndrome. Scand J Immunol. 2005;62:421–8.

    Article  Google Scholar 

  11. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:960–8.

    Article  PubMed  CAS  Google Scholar 

  12. Pincus T, Sokka T. Complexities in the quantitative assessment of patients with rheumatic diseases in clinical trials and clinical care. Clin Exp Rheumatol. 2005;23 Suppl 39:S1–9.

    PubMed  CAS  Google Scholar 

  13. Liang MH, Socher SA, Neal Roberts W, et al. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum. 1988;31(7):817–25.

    Article  PubMed  CAS  Google Scholar 

  14. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum. 2004;50:3418–26.

    Article  Google Scholar 

  15. Pincus T, Sokka T. Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. Best Pract Res Clin Rheumatol. 2003;17:753–81.

    Article  PubMed  Google Scholar 

  16. Strand V, Gladman D, Isenberg D, et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol. 1999;26:490–7.

    PubMed  CAS  Google Scholar 

  17. Valentini G, Della Rossa A, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis. 2001;60:592–8.

    Article  PubMed  CAS  Google Scholar 

  18. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363–9.

    Article  PubMed  CAS  Google Scholar 

  19. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27:261–3.

    PubMed  Google Scholar 

  20. Vitali C, Palombi G, Baldini C, et al. Sjögren’s syndrome disease damage index and disease activity index. Scoring systems for the assessment of disease damage and disease activity in Sjögren’s syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum. 2007;56:2223–31.

    Article  PubMed  Google Scholar 

  21. Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol. 1992;10:541–7.

    PubMed  CAS  Google Scholar 

  22. Bowman SJ, Sutcliffe N, Isenberg DA, et al. Sjögren’s Syndrome Clinical Activity Index (SCAI) – a systemic disease activity measure for use in clinical trials in primary Sjögren’s syndrome. Rheumatology (Oxford). 2007;46:1845–51.

    Article  CAS  Google Scholar 

  23. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86: 447–58.

    PubMed  CAS  Google Scholar 

  24. Sutcliffe N, Stoll T, Pyke S, et al. Functional disability and end organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjögren’s syndrome (SS), and primary SS. J Rheumatol. 1998;25:63–8.

    PubMed  CAS  Google Scholar 

  25. Barry RJ, Sutcliffe N, Isenberg DA, et al. The Sjögren’s syndrome Damage Index (SSDI) – a damage index for use in clinical trials and observational studies in primary Sjögren’s syndrome. Rheumatology (Oxford). 2008;47:1193–8.

    Article  CAS  Google Scholar 

  26. Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis. 2010;69:1103–9.

    Article  PubMed  Google Scholar 

  27. Seror R, Mariette X, Bowman S, et al. Accurate detection of changes in disease activity in primary Sjogren’s syndrome by the European League Against Rheumatism Sjogren’s Syndrome Disease Activity Index. Arthritis Care Res. 2010;62:551–8.

    Article  Google Scholar 

  28. Bowman SJ, Booth DA, Platts RG. Measurement of fatigue and discomfort in primary Sjogren’s syndrome using a new questionnaire tool. Rheumatology (Oxford). 2004;43: 758–64.

    Article  CAS  Google Scholar 

  29. Bowman SJ, Booth DA, Platts RG, et al. Validation of the Sicca Symptoms Inventory for clinical studies of Sjogren’s syndrome. J Rheumatol. 2003;30:1259–66.

    PubMed  Google Scholar 

  30. Seror R, Ravaud P, Mariette X, et al. EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI). Development of a consensus patient index for primary Sjögren’s syndrome. Ann Rheum Dis. 2011;70(6):968–72.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Section of Rheumatology, ‘Villamarina’ Hospital, Piombino, Italy

    Claudio Vitali

Authors
  1. Claudio Vitali
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Barcelona, Surgey, Hospital Clinic, Calle Villarroel, 170, Barcelona, 08036, Spain

    Manuel Ramos-Casals

  2. Massachusetts General Hospital, Boston, 02114, Massachusetts, USA

    John H. Stone

  3. National University of Athens, Athens, Greece

    Haralampos M. Moutsopoulos

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag London Limited

About this chapter

Cite this chapter

Vitali, C. (2011). Measurement of Chronicity and Activity in Sjögren’s Syndrome. In: Ramos-Casals, M., Stone, J., Moutsopoulos, H. (eds) Sjögren’s Syndrome. Springer, London. https://doi.org/10.1007/978-0-85729-947-5_30

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-947-5_30

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-946-8

  • Online ISBN: 978-0-85729-947-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation